Silgan Holdings (SL3) AI Stock Analysis

Company Guidance

For the fourth quarter of 2026, Silgan estimated adjusted earnings of $0.76 to $0.86 per diluted share versus adjusted EPS of $0.67 in the prior year period, with higher year-over-year adjusted EBIT of approximately $10 million to $15 million, interest expense of $45 million to $50 million, a tax rate of approximately 25% to 26%, and volumes comparable to prior year levels in all segments; Dispensing and Specialty Closures organic EBIT is expected to grow year-over-year in Q4. For full year 2026, Silgan increased adjusted EPS guidance to $3.83 to $3.93, a 4% increase at the midpoint versus $3.72 in 2025, including low single-digit percentage adjusted EBIT growth, adjusted corporate expense of approximately $45 million to $50 million, interest expense of approximately $185 million, an expected tax rate of 25% to 26%, and volumes comparable to the prior year period in all 3 segments; free cash flow is expected to be approximately $450 million, including CapEx of approximately $310 million. For 2027, Silgan expects another year of organic earnings and free cash flow growth, with some kind of modest free cash flow growth, while longer-term expectations include mid-single-digit growth in fragrance and beauty, probably closer to high single-digit growth in healthcare pharma, and low single digit growth in food and beverage.